He Yi-Fu, Zhang Yu-Jing, Li Yu-Hong, Lin Tong-Yu, Xia Yun-Fei, Lu Tai-Xiang, Huang Hui-Qiang, Jiang Wen-Qi, Xian Chao-Gui, He You-Jian, Guan Zhong-Zhen
State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, P. R. China.
Ai Zheng. 2006 Dec;25(12):1538-42.
BACKGROUND & OBJECTIVE: Primary non-Hodgkin's lymphoma (NHL) of the nasal cavity has unique clinicopathologic features, and optimal treatment regimen remains unclear. This study was to summarize the clinical features, treatment outcomes, and prognostic factors of primary NHL of the nasal cavity at early stage.
Records of 108 patients with primary NHL of the nasal cavity, consecutively treated at Cancer Center, Sun Yat-sen University from Jun. 1990 to Sep. 2004, were reviewed. All diagnoses were confirmed with pathology and immunochemistry. Seven cases were of B-cell phenotype. Survival prognostic factors were analyzed by Kaplan-Meier method and Cox regression model with SPSS12.0 software.
Median follow-up time for survived patients was 41 months. The overall complete remission (CR) rate after primary treatment was 67.6%, and CR rates were 80.2% for the patients received radiochemotherapy and 29.6% for the patients received chemotherapy alone. There were evidences indicating systemic relapse in 33 (30.6%) patients. With regard to the control of local, regional, and systemic failure, radiochemotherapy was better than chemotherapy alone. The 5-year overall survival rate was 50.0% for all patients. Both univariate analysis and multivariate analysis showed that pre-treatment history of more than 3 months, primary lesion limited in the nasal cavity, CR after primary treatment, and radiochemotherapy were favorable prognostic factors.
Nasal cavity is frequently involved by peripheral T- and NK-cell lymphomas. Pre-treatment history of disease, extent of primary lesion involvement, and response to the primary treatment may be independent prognostic factors.
鼻腔原发性非霍奇金淋巴瘤（NHL）具有独特的临床病理特征，最佳治疗方案仍不明确。本研究旨在总结鼻腔原发性NHL早期的临床特征、治疗效果及预后因素。
回顾性分析1990年6月至2004年9月在中山大学肿瘤防治中心连续治疗的108例鼻腔原发性NHL患者的病历资料。所有诊断均经病理及免疫组化证实。7例为B细胞表型。采用Kaplan-Meier法和Cox回归模型，利用SPSS12.0软件分析生存预后因素。
存活患者的中位随访时间为41个月。初始治疗后的总完全缓解（CR）率为67.6%，接受放化疗患者的CR率为80.2%，单纯接受化疗患者的CR率为29.6%。有证据表明33例（30.6%）患者出现全身复发。在控制局部、区域和全身复发方面，放化疗优于单纯化疗。所有患者的5年总生存率为50.0%。单因素分析和多因素分析均显示，治疗前病程超过3个月、原发灶局限于鼻腔、初始治疗后CR及放化疗是有利的预后因素。
鼻腔常受累于外周T细胞和NK细胞淋巴瘤。疾病的治疗前病程、原发灶受累范围及对初始治疗的反应可能是独立的预后因素。
